T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer

Published on Feb 1, 2019in Advanced Drug Delivery Reviews15.519
· DOI :10.1016/j.addr.2019.01.007
Vasyl Eisenberg2
Estimated H-index: 2
(BIU: Bar-Ilan University),
Shiran Hoogi2
Estimated H-index: 2
(BIU: Bar-Ilan University)
+ 2 AuthorsCyrille J. Cohen23
Estimated H-index: 23
(BIU: Bar-Ilan University)
Abstract The last decade will be remembered as the dawn of the immunotherapy era during which we have witnessed the approval by regulatory agencies of genetically engineered CAR T-cells and of checkpoint inhibitors for cancer treatment. Understandably, T-lymphocytes represent the essential player in these approaches. These cells can mediate impressive tumor regression in terminally-ill cancer patients. Moreover, they are amenable to genetic engineering to improve their function and specificity. In the present review, we will give an overview of the most recent developments in the field of T-cell genetic engineering including TCR-gene transfer and CAR T-cells strategies. We will also elaborate on the development of other types of genetic modifications to enhance their anti-tumor immune response such as the use of co-stimulatory chimeric receptors (CCRs) and unconventional CARs built on non-antibody molecules. Finally, we will discuss recent advances in genome editing and synthetic biology applied to T-cell engineering and comment on the next challenges ahead.
  • References (364)
  • Citations (2)
📖 Papers frequently viewed together
240 Citations
3 Authors (Jun Xu, ..., Joseph A. Fraietta)
6 Citations
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Diogo Gomes-Silva (IST: Instituto Superior Técnico)H-Index: 4
#2Erden Atilla (Center for Cell and Gene Therapy)H-Index: 1
Last. Maksim Mamonkin (BCM: Baylor College of Medicine)H-Index: 10
view all 12 authors...
Chimeric antigen receptor (CAR) T cell therapy for the treatment of acute myeloid leukemia (AML) has the risk of toxicity to normal myeloid cells. CD7 is expressed by the leukemic blasts and malignant progenitor cells of approximately 30% of AML patients but is absent on normal myeloid and erythroid cells. Since CD7 expression by malignant blasts is also linked with chemoresistance and poor outcomes, targeting this antigen may be beneficial for this subset of AML patients. Here, we show that exp...
6 CitationsSource
#1Li Zhang (BCM: Baylor College of Medicine)H-Index: 24
#2Tomasz Sosinowski (University of Colorado Denver)H-Index: 6
Last. Howard W. Davidson (University of Colorado Denver)H-Index: 34
view all 10 authors...
Abstract A primary initiating epitope in the NOD mouse model of Type 1 Diabetes (T1D) lies between residues 9 and 23 of the insulin B chain. The B:9-23 peptide can bind to the NOD MHC class II molecule (I-Ag7) in multiple registers, but only one, (register 3, R3), creates complexes able to stimulate the majority of pathogenic B:9-23-specific CD4+ T cells. Previously we generated a monoclonal antibody (mAb287) that targets this critical I-Ag7-B:9-23(R3) complex. When given weekly to pre-diabetic ...
3 CitationsSource
#1Carlos A. Ramos (BCM: Baylor College of Medicine)H-Index: 34
#2Rayne H. Rouce (BCM: Baylor College of Medicine)H-Index: 10
Last. Gianpietro Dotti (BCM: Baylor College of Medicine)H-Index: 61
view all 21 authors...
Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B cell malignancies, but it is unknown whether any of the costimulatory domains incorporated in the CAR have superior activity to others. Because CD28 and 4-1BB signaling activate different pathways, combining them in a single third-generation (3G) CAR may overcome the limitations of each individual costimulatory domain. We designed a clinical trial in which two autologous CD19-specific CAR-transduc...
12 CitationsSource
#1Tatsuo Matsuda (U of C: University of Chicago)H-Index: 3
#2Matthias Leisegang (Charité)H-Index: 15
Last. Yoshio Nakamura (U of C: University of Chicago)H-Index: 164
view all 11 authors...
Purpose: Current evolution of cancer immunotherapies, such as immune checkpoint blockade, has implicated neoantigens as major targets of anti-cancer cytotoxic T cells. Adoptive T cell therapy with neoantigen-specific T cell receptor (TCR)-engineered T cells would be an attractive therapeutic option for advanced cancers where the host anti-tumor immune function is strongly inhibited. We previously developed a rapid and efficient pipeline for production of neoantigen-specific TCR-engineered T cell...
16 CitationsSource
#1Anett Pfeiffer (Paul Ehrlich Institute)H-Index: 2
#2Frederic B. Thalheimer (Paul Ehrlich Institute)H-Index: 2
Last. Christian J. Buchholz (DKFZ: German Cancer Research Center)H-Index: 28
view all 12 authors...
Abstract Chimeric antigen receptor (CAR) T cells brought substantial benefit to patients with B‐cell malignancies. Notwithstanding, CAR T‐cell manufacturing requires complex procedures impeding the broad supply chain. Here, we provide evidence that human CD19‐CAR T cells can be generated directly in vivo using the lentiviral vector CD8‐LV specifically targeting human CD8 + cells. Administration into mice xenografted with Raji lymphoma cells and human peripheral blood mononuclear cells led to CAR...
10 CitationsSource
#1Alexey Stepanov (RAS: Russian Academy of Sciences)H-Index: 8
#2Oleg V. Markov (RAS: Russian Academy of Sciences)H-Index: 5
Last. Richard A. Lerner (Scripps Research Institute)H-Index: 95
view all 17 authors...
We report the development of a novel platform to enhance the efficacy and safety of follicular lymphoma (FL) treatment. Since lymphoma is a clonal malignancy of a diversity system, every tumor has a different antibody on its cell surface. Combinatorial autocrine-based selection is used to rapidly identify specific ligands for these B cell receptors on the surface of FL tumor cells. The selected ligands are used in a chimeric antigen receptor T cell (CAR-T) format for redirection of human cytotox...
3 CitationsSource
#1Kaichao Feng (Chinese PLA General Hospital)H-Index: 11
#2Yang Liu (Chinese PLA General Hospital)H-Index: 12
Last. HanWei-Dong (Chinese PLA General Hospital)H-Index: 28
view all 9 authors...
This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (PCs). Eligible patients with HER2-positive (>50%) BTCs and PCs were enrolled in the trial. Well cultured CART-HER2 cells were infused following the conditioning treatment composed of nab-paclitaxel (1...
20 CitationsSource
#1Marco RuellaH-Index: 21
#2Jun Xu (UPenn: University of Pennsylvania)H-Index: 6
Last. J. Joseph Melenhorst (UPenn: University of Pennsylvania)H-Index: 7
view all 26 authors...
We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19– leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.
58 CitationsSource
#1Felicitas Rataj (LMU: Ludwig Maximilian University of Munich)H-Index: 6
#2Fabian B. T. Kraus (LMU: Ludwig Maximilian University of Munich)H-Index: 2
Last. Sebastian Kobold (LMU: Ludwig Maximilian University of Munich)H-Index: 15
view all 9 authors...
Background: Interaction of the programmed death receptor 1 (PD-1) and its ligand, PD-L1, suppresses T cell activity and permits tumors to evade T cell-mediated immune surveillance. We have recently demonstrated that antigen-specific CD8+ T cells transduced with a PD1-CD28 fusion protein are protected from PD-1-mediated inhibition. We have now investigated the potential of PD1-CD28 fusion protein-transduced CD4+ T cells alone or in combination with CD8+ T cells for immunotherapy of pancreatic can...
6 CitationsSource
#1In-Young JungH-Index: 2
#2Yoon-Young KimH-Index: 1
Last. Jungmin LeeH-Index: 4
view all 6 authors...
The efficacy of T cell therapy is inhibited by various tumor-associated immunosuppressive ligands and soluble factors. Such inhibitory signals turn specific T cell signaling pathways on or off, impeding the anti-cancer functions of T cells. Many studies have focused on PD-1 or CTLA-4 blockade to invigorate T cell functions through CD28/B7 signaling, but obtaining robust clinical outcomes remains challenging. In this study, we use CRISPR/Cas9 to potentiate T cell function by increasing CD3 signal...
14 CitationsSource
Cited By2
#1Chengui Lu (Xinxiang Medical University)H-Index: 1
#2Changjiang Guo (Xinxiang Medical University)H-Index: 1
Last. Wuling Zhu (Xinxiang Medical University)H-Index: 1
view all 10 authors...
Abstract Chimeric antigen receptor (CAR)-modified adoptive natural killer (NK) cells represent a promising immunotherapeutic modality for cancer treatment but face many challenges in solid tumors. One major obstacle is the immune-suppressive effects induced by inhibitory receptors (IR) including PD1. To interfere with PD1 signaling to augment CAR-NK cells’ activity against solid tumors, we rationally designed a novel chimeric costimulatory converting receptor (CCCR), comprising mainly the extrac...
#1Yonggui Tian (Zhengzhou University)H-Index: 1
#2Yilu Li (Zhengzhou University)H-Index: 1
Last. Yi Zhang (Zhengzhou University)H-Index: 59
view all 4 authors...
: Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies. However, CAR T therapy against solid tumors is less effective. Antigen targeting; an immunosuppressive tumor microenvironment (TME); and the infiltration, proliferation, and persistence of CAR T cells are the predominant barriers preventing the extension of CAR T therapy to solid tumors. To circumvent t...
1 CitationsSource
#1Sara Meril (BIU: Bar-Ilan University)H-Index: 1
#2Ortal Harush (BIU: Bar-Ilan University)H-Index: 1
Last. Cyrille J. Cohen (BIU: Bar-Ilan University)H-Index: 23
view all 6 authors...
Chimeric antigen receptor (CAR) T-cells treatment demonstrate the increasing and powerful potential of immunotherapeutic strategies, as seen mainly for hematological malignancies. Still, efficient CAR-T cell approaches for the treatment of a broader spectrum of tumors are needed. It has been shown that cancer cells can implement strategies to evade immune response that include the expression of inhibitory ligands, such as hypersialylated proteins (sialoglycans) on their surface. These may be rec...
1 CitationsSource
#1Shiran Hoogi (BIU: Bar-Ilan University)H-Index: 2
#2Vasyl Eisenberg (BIU: Bar-Ilan University)H-Index: 2
Last. Cyrille J. Cohen (BIU: Bar-Ilan University)H-Index: 23
view all 6 authors...
Background Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the function of latter. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is such a co-inhibitory receptor expressed by T and NK cells which, upon binding to its ligand (e.g., CD155), can diminish cytokine production and effector function. Additionally, the absence of positive co-st...
1 CitationsSource
#1Roland PreeceH-Index: 2
#2C GeorgiadisH-Index: 4
Gene editing tools are being rapidly developed, accelerating many areas of cell and gene therapy research. Each successive gene editing technology promises increased efficacy, improved specificity, reduced manufacturing cost and design complexity; all of which are currently epitomised by the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein (Cas9) platform. Since its conceptualisation, CRISPR-based gene editing has been applied to existing methodolo...
1 CitationsSource